Jetstar to Charge for Overhead Cabin Bags From February 
Apple Restores Telegram to App Store After Content Policy Violation 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
CAMBRIDGE, Mass., March 21, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced that it will host a conference call and webcast on Wednesday, March 28th, 2018, at 8:00 a.m. ET to report financial results for the fourth quarter and full year 2017 and provide business updates.
To access the call, please dial 866-363-0156 (domestic) or 706-902-3589 (international) and provide the Conference ID 2057979. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1522, is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Contacts:
Media Contact
Paul Kidwell, 617-680-1088
[email protected]
Or
Investor Contact
Stern Investor Relations, Inc.
Christina Tartaglia, 212-362-1200
[email protected]
